Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

878.24
-18.7600-2.09%
Post-market: 875.00-3.2400-0.37%19:59 EDT
Volume:2.74M
Turnover:2.43B
Market Cap:830.27B
PE:38.27
High:900.83
Open:896.00
Low:877.11
Close:897.00
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.94
T/O Rate:0.29%
Dividend:6.00
Dividend Rate:0.68%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:31.29
PE(LYR):38.27

Loading ...

Eli Lilly’s New Diabetes Candidate LY3549492 Advances With Completion of Early-Stage Study in Japan

TIPRANKS
·
Mar 21

BMO Capital Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
Mar 20

Market Chatter: Eli Lilly Alzheimer's Drug to be Reconsidered by UK Health Regulator

MT Newswires Live
·
Mar 20

Eli Lilly Wins Appeal for Alzheimer's Drug, Prompting NHS Review of Coverage

Stock News
·
Mar 20

Health Rounds: Diabetes patients who stop GLP-1 drugs increase their heart risks

Reuters
·
Mar 20

Eli Lilly Advances EMERALD-3: A New Oral Bet in Ulcerative Colitis

TIPRANKS
·
Mar 20

US FDA approves higher dose of Novo's Wegovy under new fast-track review program

Reuters
·
Mar 20

Eli Lilly data compare favorably to Mounjaro, Ozempic, says Deutsche Bank

TIPRANKS
·
Mar 19

Eli Lilly retatrutide results ‘favorable,’ but similar to Mounjaro, says Truist

TIPRANKS
·
Mar 19

Eli Lilly Stock (LLY) Rises. The Pharma Giant Has Reported Some Very Good News

TIPRANKS
·
Mar 19

Eli Lilly's 'Triple Agonist' Is More Than Just a Weight-Loss Drug. This Trial Proves It. -- Barrons.com

Dow Jones
·
Mar 19

Lilly's Retatrutide Slashes Both Weight Loss and Blood Sugar Levels in Landmark Study -- Update

Dow Jones
·
Mar 19

Lilly Phase 3 TRANSCEND-T2D-1 trial shows retatrutide cuts A1C up to 2% and weight 16.8%

Reuters
·
Mar 19

Lilly's Triple Agonist, Retatrutide, Demonstrated Significant Reductions in a1c and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes

THOMSON REUTERS
·
Mar 19

Eli Lilly: Retatrutide Showed Significant Reductions in a1c & Weight in First Phase 3 Trial for Type 2 Diabetes Treatment

THOMSON REUTERS
·
Mar 19

BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial

Reuters
·
Mar 19

Eli Lilly: Participants Taking Retatrutide 12 Mg Lost Average of 36.6 Lbs

THOMSON REUTERS
·
Mar 19

Eli Lilly: No Weight Loss Plateau Was Observed With Retatrutide

THOMSON REUTERS
·
Mar 19

Eli Lilly: Retatrutide Showed Clinically Meaningful Improvements From Baseline Across Key Cardiovascular Risk Factors

THOMSON REUTERS
·
Mar 19

Eli Lilly: Retatrutide Lowered a1c by Average of 1.7%-2.0% Across Doses at 40 Weeks in Transcend-T2d-1 Trial

THOMSON REUTERS
·
Mar 19